Right now is a critical time for the healthcare industry to evaluate how patients are financially burdened by novel treatments that can provide tremendous outcomes, said Joshua R. Richter, MD, of the John Theurer Cancer Center.
Right now is a critical time for the healthcare industry to evaluate how patients are financially burdened by novel treatments that can provide tremendous outcomes, said Joshua R. Richter, MD, of the John Theurer Cancer Center.
Transcript
As new, more expensive treatments improve survival, how can clinicians identify and address the burden of financial toxicity?
I think this is something that's really critical and is becoming more and more of an issue that we can no longer, as physicians, bury our heads in the sand, and need to, kind of, understand where the difficulty comes in with this. We have a lot of new drugs and these drugs may offer many of our patients tremendous outcomes, but there is also a significant amount of financial burden that does come across, not only to the patient, but to their family. And while some of this is simply perceived by the patient, some of this can be quite real, and patients often plunge themselves into deep financial troubles in order to support the care for their own disease, and this may affect their family, as well.
So, this is really kind of a critical time for us to evaluate things on a global standpoint. Yes, we need to be concerned about the system as a whole, but we need to get more granular, and focus on what are the deleterious effects that we're seeing on a patient-by-patient level in terms of the financial burden that we're seeing with these great new therapies.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence
May 13th 2024Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Read More